Asset
Rezpegaldesleukin
Nektar Therapeutics Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05565729 | phase1 | completed | 2022-10-05 | 2023-02-23 | Nektar Therapeutics | A Phase I Study of LY3471851 in Healthy Participants |
| NCT04998487 | phase1 | completed | 2021-08-16 | 2022-07-06 | Nektar Therapeutics | A Single-Dose Study of LY3471851 in Healthy Participants |
| NCT04677179 | phase2 | terminated | 2021-03-22 | 2022-08-09 | Nektar Therapeutics | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) |
| NCT04433585 | phase2 | completed | 2020-08-19 | 2023-01-10 | Nektar Therapeutics | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) |
| NCT04133116 | phase1 | completed | 2019-10-29 | 2020-03-06 | Nektar Therapeutics | A Study of LY3471851 in Healthy Participants |
FDA applications (0)
This company has no applications containing this asset.